Positron Receives U.S. Patent For Solid State Sensors
CHICAGO, Oct. 16, 2012 /PRNewswire/ -- Positron
Corporation (OTCBB:POSC), announced today that the United States
Patent and Trademark Office (USPTO) has awarded the Company a
patent (U.S. No. 8,269,181) for its original semiconductor detector
used in high precision measuring of coordinates and detection of
ionization particles. The technology and patent issuance was
achieved through collaboration with Dr. Valeri Saveliev of DESY in Hamburg, Germany. Dr. Saveliev's expertise in
avalanche pixel sensors and related methods were instrumental in
the development of the solid state technology.
The detector structure has two collinear layers of avalanche
microcells with high internal amplification and is capable of
detecting low energy ionization particles by overcoming a
fundamental limitation of the precision coordinate measuring of
ionization particles–multiple scattering in material. The detector
is not sensitive to photons and completely eliminates the dark rate
as background.
Due to a high signal to noise ratio, the detection and
coordinate measuring can be achieved on a chip without special
on-chip readout electronics and/or additional external electronics,
which can significantly reduce the cost of the detection or imaging
equipment. The detector is small, robust, and operates at an
extremely low voltage.
The detector has a number of potential applications in medical
imaging, radiotherapy (photon therapy, electron therapy, hadron
therapy), homeland security, experimental physics, and Auger
electrons dosimeters.
"Positron's patented technology makes it possible to provide
radiotherapy systems at a lower cost with an increased precision of
treatment, thus limiting the damage to normal tissue. This
technology will also provide a less expensive, much smaller
detector, with an increased capability to localize the source(s) of
ionizing radiation, for Homeland Security. This technology may be
very valuable in the future for Positron as we continue to add
value to our product portfolio. Positron is proud to have
shared in this collaboration and to be associated with such a
highly respected scientist as Dr. Saveliev," stated Patrick Rooney, Positron's chief executive
officer.
About Positron: Positron Corporation is a nuclear
medicine healthcare company vertically integrating all the segments
of nuclear cardiology—providing an end-to-end solution for cardiac
PET. Through proprietary PET imaging systems,
radiopharmaceuticals and radioisotopes solutions, Positron enables
healthcare providers to more accurately diagnose disease and
improve patient outcomes, while practicing cost effective medicine.
Positron's unique products, market position and approach in
securing the supply chain are substantial advantages, further
accelerating the adoption of cardiac PET and growth of nuclear
cardiology. Positron is redefining the industry. More
information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this
document contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not
guarantees of future performance. These statements may involve
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of Positron
Corporation to be materially different from future results,
performance or achievements expressed or implied by such
forward-looking statements. Positron assumes no obligation to
publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking
statements, even if new information becomes available in the
future. Our actual results may differ materially from the
results anticipated in these forward-looking statements due to a
variety of factors, including, without limitation those set forth
as "Risk Factors" in our filings with the Securities and Exchange
Commission.
SOURCE Positron Corporation